Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 14

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 14
---
 in ways that may not enhance our operating results or the price of our Ordinary Shares.                                                                                                                                                                      |

| ● | New investors purchasing our securities will experience immediate and substantial dilution |

<div align='center'>7</div>

Risks Related to Israeli Law and Our Operations in Israel

| ● | Political, economic and military instability in the State of Israel, including as a result of the “Iron Swords” war on Israel, where our headquarters, members of our management team and our research and development facilities are located, may adversely affect our results of operations.                                                                                        |
| ● | Our operations may be disrupted as a result of the obligation of management or key personnel to perform military service.                                                                                                                                                                                                                                                             |
| ● | The termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.                                                                                                                                                                                                                                  |
| ● | We may be required to pay monetary remuneration to our Israeli employees for their inventions, even if the rights to such inventions have been duly assigned to us.                                                                                                                                                                                                                   |
| ● | We received Israeli government grants for certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions, we may be required to pay penalties and refund grants previously received. |

| ● | We may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.                                                                                                                                                                                                        |
| ● | Provisions of Israeli law and our amended and restated articles of association to be in effect upon the completion of this offering may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders. |

| ● | It may be difficult to enforce a judgment of a U.S. court against us and our executive officers and directors and the Israeli experts named in this prospectus in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our executive officers and directors and these experts. |
| ● | Your rights and responsibilities as a shareholder will be governed in key respects by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.                                                                                                            |

<div align='center'>8</div>

Corporate Information We are an Israeli corporation based in Israel and incorporated